"Approvable" letter received May 18 for once-daily OROS formulation of methylphenidate for ADD/ADHD. FDA is not requesting additional clinical data, and the companies continue to plan for a fall launch (1"The Pink Sheet" April 24, p. 7). The NDA was submitted July 21, 1999
You may also be interested in...
Alza and McNeil Consumer Healthcare are preparing a combined sales force of 420 reps to detail Alza's once-daily methylphenidate treatment Concerta for pediatric attention deficit/hyperactivity disorder.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials